BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG per actuation

AEROSOL, METERED

**4.2 Posology and method of administration** The recommended and maximum dose is two inhalations of BREZTRI AEROSPHERE 160/7.2/5.0 twice daily, in the morning and in the evening, by the orally inhaled route only. **Missed dose** If a dose is missed, it should be taken as soon as possible, and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose. **Children** There is no relevant use of BREZTRI AEROSPHERE in children and adolescents (under 18 years of age) in the indication of COPD. **Dosage in patients with renal impairment:** No dosage adjustment is necessary for patients with renal impairment (see section 4.4 and section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Dosage in patients with hepatic impairment:** No dosage adjustment is necessary for patients with hepatic impairment (see section 4.4 and section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Elderly:** No dosage adjustment is necessary for elderly patients (see section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Method of administration** For oral inhalation use. For detailed instructions, refer to the patient leaflet – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Patients should be instructed how to administer the product correctly and advised to read the instructions for use carefully. Patients who find it difficult to co-ordinate actuation with inhalation may use BREZTRI AEROSPHERE with a spacer to ensure proper administration of the product. BREZTRI AEROSPHERE can be used with spacer devices including the Aerochamber Plus® Flow Vu®.